Department of Defense is again demonstrating its support of pathogen inactivation,’ said Dr. Laurence Corash, Cerus’ chief medical officer. ‘This award will allow Cerus to aid ongoing advancement of the INTERCEPT red cell system.’ The award, granted by the U.S. Army Medical Analysis Acquisition Activity, between August 2011 and August 2012 addresses a performance period. The award was granted to Cerus in recognition of the INTERCEPT crimson blood system’s potential to provide U.S. Military personnel with prospective safety against transfusion-transmitted illnesses. To time, Cerus has received more than $32 million in financing from the U.S. Department of Defense to boost blood safety for the U.S. Military.. Cerus to support ongoing advancement of INTERCEPT crimson cell system Cerus Corporation announced today that it has received a $2.1 million award from the U.S.Related StoriesMeat-rich diet plan may increase kidney tumor riskNew RNA check of blood platelets may be used to detect area of cancerStudy shows uncommon HER2 missense mutations usually do not spread breasts cancer on the ownResearchers disagree on the amount of risk connected with splenectomy. A scholarly study by Dr. M. Domenica Cappellini, a co-author of the extensive research, found that thirty % of splenectomized thalassemia intermedia individuals developed clots. Nevertheless, a recently available study of 8,860 splenectomized sufferers with thalassemia main and thalassemia intermediate discovered that the price of thrombolytic occasions was 1.75 %.